BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
1763277
Number of visits today
864
Number of downloads
1012367
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Dolmans MM, Cacciottola L, Donnez J. Conservative Management of Uterine Fibroid-Related Heavy Menstrual Bleeding and Infertility: Time for a Deeper Mechanistic Understanding and an Individualized Approach. J Clin Med 2021;10:4389. [PMID: 34640407 DOI: 10.3390/jcm10194389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Maidarti M, Anggraheny BAR, Umarghanies SS, Garinasih PD, Harzif AK, Simatupang ONN. Severe chronic pelvic pain due to cystic degeneration of subserosal uterine fibroid with type 2 diabetes and obesity: Serial case report. Int J Surg Case Rep 2023;104:107934. [PMID: 36801770 DOI: 10.1016/j.ijscr.2023.107934] [Reference Citation Analysis]
2 Vannuccini S, Clemenza S, Cassioli E, Rossi E, Castellini G, Ricca V, Petraglia F. Uterine Fibroids, Perceived Stress, and Menstrual Distress: a Key Role of Heavy Menstrual Bleeding. Reprod Sci 2022. [DOI: 10.1007/s43032-022-01126-3] [Reference Citation Analysis]
3 Akram S, Akmal A, Ahmad S, Ahmad H, Roohi N. Clinicopathological Patterns and Biochemical Markers in Serum of Uterine Leiomyoma Patients. Albus Scientia 2022;2022:1-7. [DOI: 10.56512/as.2022.2.e221025] [Reference Citation Analysis]
4 Donnez J, Carmona F, Maitrot-Mantelet L, Dolmans MM, Chapron C. Uterine disorders and iron deficiency anemia. Fertil Steril 2022;118:615-24. [PMID: 36182260 DOI: 10.1016/j.fertnstert.2022.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet 2022;400:896-907. [PMID: 36116480 DOI: 10.1016/S0140-6736(22)01475-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
6 Keam SJ. Linzagolix: First Approval. Drugs 2022. [PMID: 35997940 DOI: 10.1007/s40265-022-01753-9] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345